Core Viewpoint - The article discusses the discovery and potential of a new anti-obesity peptide called BRP (BRINP2-related peptide), which shows promise in reducing food intake and body weight without causing adverse effects, marking a significant advancement in obesity treatment [7][12][20]. Summary by Sections Peptide Hormones and Obesity Treatment - Peptide hormones play a crucial role in regulating energy balance and appetite, making them ideal targets for obesity treatment. Over the past 40 years, 12 appetite-regulating peptides have been identified [6][9]. Discovery of BRP - A research team from Stanford University reported the discovery of BRP, which effectively reduces food intake in mouse and pig models without causing nausea. The mechanism involves activation of the FOS protein in the central nervous system, independent of leptin and GLP-1 receptor pathways [7][12]. Mechanism of Action - BRP's action is linked to the CREB-FOS signaling pathway, with studies showing that it activates specific neuronal pathways in the hypothalamus, crucial for appetite suppression [20][22]. Efficacy in Animal Models - In studies, BRP demonstrated a significant reduction in food intake in mice, with a dose of 5 mg/kg leading to a notable decrease in consumption. In pig models, BRP also reduced food intake by 50% within one hour, comparable to GLP-1 receptor agonists [13][15][17]. Safety Profile - BRP was shown to have no adverse effects on animal behavior, activity levels, or other physiological parameters, distinguishing it from other weight loss drugs that may cause side effects [14][19]. Potential for Human Application - The findings suggest that BRP could be a groundbreaking option for obesity treatment, offering a new avenue for weight management without the side effects commonly associated with existing therapies [22].